Alzheimer’s disease (AD) is a type of dementia characterized by an age-related progressive decline in mental ability. It is characterized by the extracellular accumulation of amyloid beta (Aβ) peptide and intracellular aggregates of protein tau (neurofibrillary tangles). For many years, these pathological processes were considered the main cause of synaptic degeneration and cell death. Accordingly, many treatments aimed at reducing and/or preventing amyloid plaque formation were proposed during these years. However, many clinical trials, based on information from AD animal models, were not effective in human AD patients. For these reasons, the amyloid cascade hypothesis has been modified. In details, it was observed that the...
accumulation and deposition of Aβ in the brain is not sufficient to cause the disease as healthy subjects may also present plaques morphologically similar to those of AD patients.4,5

Recent studies have shown that soluble forms of Aβ and tau proteins could be more toxic than aggregated forms.6,8 This mechanism is still not clear, but it has been hypothesized that soluble forms may target specific synaptic sites and disrupt synaptic signaling pathways, thus altering memory functions and causing at least the death of the neuron.6,8,11 It has been proposed that the plaques represent an initial attempt to sequester soluble forms from extracellular space and preclude their toxicity.12 Later on, when the sequestering capacity of the plaques is reduced once they become saturated, soluble forms are free to diffuse in the synaptic space and to bind synaptic sites, causing AD memory deficits.13 This hypothesis has been supported by electrophysiological data showing that soluble Aβ forms may alter long-term potentiation (LTP) and thus memory processes in hippocampal neurons.14,16 Moreover, it was shown that soluble Aβ42 oligomers taken from the brain of AD patients affect hippocampal function in rodents by enhancing long-term depression (LTD), inhibiting LTP, and decreasing the number of synapses.14

These findings have encouraged the researchers to focus on the identification of the neuronal pathways targeted by soluble forms, in the attempt to develop new therapeutic approaches.17 One of the possible pathways explored in this review is represented by the neurotrophin brain-derived neurotrophic factor (BDNF) and the process that leads to the maturation from the pro-form (pro-BDNF) to the biologically active form (BDNF). This process in brain neurons is regulated extracellularly by enzymes of the plasminogen activation system.

2 | THE PLASMINOGEN ACTIVATION SYSTEM IN THE CENTRAL NERVOUS SYSTEM

The plasminogen activation system is a system composed by different enzymes that control the synthesis of plasmin. The urokinase plasminogen activator (uPA) and the tissue-type plasminogen activator (tPA) are the enzymes that activate the process of transformation from plasminogen to plasmin. Their activity is in turn regulated by PA inhibitor type 1 (PAI-1) and type 2 (PAI-2) and nexin.18 In the brain, it has been demonstrated that activation of plasmin is typically dependent on the tPA/PAI-1 enzymes.

Outside the CNS, the plasminogen activation system is implicated in fibrinolytic mechanisms because the substrate of plasmin is fibrin.19 However, tPA can be expressed by cellular elements of the CNS, including neurons, astrocytes, oligodendrocytes, and microglia.20,21 This suggests that tPA might be involved in many functions within the brain.21

During development, tPA has a role in neuronal migration and synaptic outgrowth, while in the adult brain tPA can modulate neurotransmission, synaptic plasticity, and cognitive functions.22-24 In adult neurons, tPA is synthesized and stored in vesicles25,26 and it is released extracellularly upon neuronal depolarization.27,28

| Tissue                      | Species | Result                                                                 | References |
|-----------------------------|---------|------------------------------------------------------------------------|------------|
| Neuronal cultures           | Rat, Mouse | Plasmin degrades Aβ                                                   | 33,34,36   |
| Neuronal cultures           | Rat     | Plasmin protects neurons from Aβ-induced cell death                    | 33,34      |
| Brain homogenates           | Human   | Plasmin reduced level and activity in AD                               | 35,37,38   |
| Brain                       | Mouse   | Plasmin reduced level and activity in AD                               | 39         |
| Brain                       | Human   | tPA reduced activity in AD                                             | 41         |
| Brain                       | Human   | tPA negatively correlates to Aβ levels in AD                          | 42         |
| Brain                       | Human   | tPA protein levels are unchanged or increased in AD                    | 41,42      |
| Brain                       | Mouse   | PAI-1 levels increased in AD models                                    | 39,40      |
| Brain                       | Human   | PAI-1 increased in AD                                                  | 44         |
| Brain                       | Human   | PAI-1 increased in MCI                                                 | 45         |
| Brain                       | Mouse   | PAI-1 increases Aβ accumulation during aging                           | 46         |
| Plasma                      | Human   | PAI-1 levels increases in AD as dementia progresses                    | 47         |

AD: Alzheimer’s disease; Aβ: amyloid beta; PAI-1: plasminogen activator inhibitor-1; tPA: tissue-type plasminogen activator.
Table 2: Main findings on BDNF in Alzheimer’s disease patients

| Tissue | Species | Result | References |
|--------|---------|--------|------------|
| Serum  | Human   | Decreased BDNF levels in AD | 87,89,92-95 |
| Serum  | Human   | Decreased BDNF levels in MCI | 87,92 |
| Serum  | Human   | Increased or unchanged BDNF levels | 88,89,97 |
| CSF    | Human   | Decreased BDNF levels in MCI and AD | 94,98,100 |
| CSF    | Human   | Unchanged BDNF levels in AD | 90 |
| Brain  | Human   | Reduced BDNF mRNA and protein levels in AD | 101-103 |
| Brain  | Human   | Reduced pro-BDNF levels | 104-106 |
| Brain  | Human   | Reduced TrkB receptor immunoreactivity in AD | 107 |
| Brain  | Human   | No changes in TrkB receptor immunoreactivity in AD | 108,109 |

AD, Alzheimer’s disease; BDNF, brain-derived neurotrophic factor; CSF, cerebrospinal fluid; MCI, mild cognitive impairment; TrkB, tyrosine kinase receptor B.

In addition, brain tissue (hippocampus and neocortex) homogenates from AD patients have reduced plasmin levels. Nonetheless, in other studies, it was shown that plasminogen and plasmin protein levels were not significantly altered in frontal and temporal cortex homogenates from AD patients.

As for plasmin, there are data indicating that tPA and PAI-1 can be altered in AD. tPA has been shown to be highly expressed in the brain areas where plaques are deposited. Nonetheless, in AD animal models where endogenous tPA was genetically reduced, a greater accumulation of Aβ was observed, in association with synaptic dysfunction and memory deficits. In addition, it was shown that tPA-mediated plasmin activity declines throughout the brain, causing Aβ deposition during aging. Similarly, in humans, it was found that tPA activity is reduced in the brain of AD patients as compared to controls and negatively correlates to Aβ levels, while tPA protein levels are unchanged or increased.

Conversely, it has been shown that PAI-1 is elevated in AD. This increase has been reported in the brain of animal models and in humans. In addition, in AD mice, it was shown that PAI-1 expression and activity contribute to Aβ accumulation during aging, a phenomenon that can be probably attributed to the inhibition of plasminogen activation and to the related reduction of Aβ degradation. These findings have been paralleled by data in plasma of AD patients where PAI-1 levels were found increased (as dementia progressed) and correlated with the decline in cognitive function.

4 | MECHANISM OF ACTION OF Aβ ON THE PLASMINOGEN ACTIVATION SYSTEM

As stated before, tPA and PAI-1 are produced by elements of the CNS, including neurons and glial cells. The information gained from AD animal models indicate that, as the level of Aβ increases, there is a concomitant overproduction of PAI-1 and a decrease in tPA/plasmin activity. Regarding the possible mechanism, it has been suggested that the reduction of tPA activity, which can cause a greater Aβ accumulation, is due to the overproduction of PAI-1 by CNS cells rather than to a direct effect of Aβ. In fact, increased amount of Aβ peptides during AD course do not affect, or even increase, the protein levels of brain tPA (and plasmin). On the opposite, it has been suggested that Aβ can stimulate, directly or indirectly, PAI-1 expression in neuronal and glial cells. Supporting this notion, it was found that increased PAI-1 levels are present in regions where Aβ accumulates, such as cerebral cortex, but not in other brain Aβ-free areas.

In some rodent studies, it was found that overproduction of PAI-1 mainly occurs in the presence of gliosis associated with Aβ load. As astrocytes are a main source of PAI-1, the authors suggest that astrogliosis induced by Aβ may be responsible for the increase in PAI-1. The presence of pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF-α), may also concur to stimulate PAI-1 expression. Alternatively, we cannot rule out the possibility that Aβ may directly stimulate PAI-1 expression by neurons. One immuno-histochemistry study, performed to localize PAI-1 in the CNS, found...
a positive immunostaining not only in astrocytes but also in rat and human neurons, with greater neuronal expression in the presence of inflammatory processes, which are common in the brain of AD patients. Furthermore, it has been shown that direct injection of Aβ into brain regions may cause an increase of PAI-1. Injection of Aβ 1-40 into CA1 region of the hippocampus of mice lacking tPA or plasminogen causes a strong PAI-1 accumulation but not in the wild type. In addition, primary cortico-hippocampal cultures from mouse AD model (Tg2576) cultured in the presence of the pathogenic fragment Aβ25-35 immediately show a dramatic increase in PAI-1 synthesis through activation of JNK-dependent c-Jun pathways.

Altogether these data indicate that the changes in the expression of plasminogen activators and inhibitors may occur during AD course and account, at least in part, for Aβ accumulation and lack of degradation. However, these proteins have other actions that may be relevant in AD. Among the events linked to the expression of these enzymes, there is also the regulation of gene expression of neurotransmitters and other proteins involved in the regulation of synaptic function and in the survival of neurons affected during AD. Among these proteins, the neurotrophin brain-derived neurotrophic factor (BDNF) has generated considerable interest because of the effects that altered levels of this protein may have on CNS neurons. Since the demonstration that the conversion from pro-BDNF to mature BDNF is regulated by plasminogen activation system, the link between this system and BDNF metabolism has been investigated.

5 | PLASMINOGEN ACTIVATION SYSTEM AND THE REGULATION OF BDNF MATURATION

In the CNS, BDNF maturation is dependent on tPA/plasmin system. Plasmin activates the extracellular conversion from pro-BDNF to the mature form and this process is regulated by PAI-1. At the same time, plasmin activity in the brain is typically dependent on tPA. Thus, tPA/PAI-1 system represent an important regulator of extracellular BDNF/pro-BDNF ratio.

It has been shown that exogenous tPA administration increases hippocampal BDNF levels and the conversion of pro-BDNF to BDNF by plasmin is essential for LTP late-phases. In addition, a defective tPA/plasmin/PAI-1-mediated BDNF maturation has been claimed to be involved in the manifestation of some brain pathologies, such as substance abuse and addiction, depression, and stress.

These data are not surprising given the fact that pro-BDNF and BDNF may have opposite effects on survival and function of CNS neurons.

6 | ROLE OF BDNF AND PRO-BDNF IN THE CNS

Brain-derived neurotrophic factor is the most abundant neurotrophin in the brain and is present and utilized in many brain regions, including cortex, hippocampus, striatum, hypothalamus, and cerebellum. It has been established that BDNF mediates survival and differentiate activities on neurons by binding and activating the tropomycin receptor kinase B (TrkB).

BDNF is synthesized as a precursor (pro-BDNF), which is cleaved by hormone convertases or by plasmin extracellularly to release the mature form. The pro-BDNF was initially described as an inactive precursor. However, it was lately shown that pro-BDNF acts as independent ligand activating the p75 receptor, rather than TrkB. The p75 receptor is a member of the tumor necrosis factor family that encodes a cytoplasmic apoptotic death domain. The p75 receptor binds to the mature domain region of pro-BDNF. Indeed, treatment of neurons that express p75 with recombinant pro-BDNF induces cell death.

In neurons, transcription, processing, and secretion of BDNF are regulated by synaptic activity. This fact has generated the idea that BDNF may regulate activity-dependent forms of synaptic plasticity, such as for example LTP. On the other hand, there are indications that the activation of pro-BDNF through the p75 receptor may produce opposite effects on hippocampal neurons. In pro-BDNF-expressing mice, it has been shown that pro-BDNF negatively regulates hippocampal dendritic complexity and spine density. In addition, hippocampal slices from these mice display reduced synaptic activity and enhanced LTD. Expression of pro-BDNF may also elicit additional effects, such as growth cone retraction, axonal pruning, LTD induction, and synaptic elimination of neuromuscular junctions. These effects contrast with those elicited by BDNF, leading to the “yin-yang” neurotrophin hypothesis in which mature BDNF and pro-BDNF exhibit opposing functions mediated by the activations of their respective receptors, TrkB and p75.

These data suggest that the conversion from the pro-BDNF to the mature BDNF is an important process that regulates hippocampal activity and memory processes. Thus, alteration of the BDNF/pro-BDNF rate of conversion may have relevance to several brain pathologies, including neurodegenerative disorders such as AD.

7 | DATA ON BDNF AND PRO-BDNF IN AD

Brain-derived neurotrophic factor expression has been investigated in the brain and serum of AD patients (Table 2). Many studies showed that AD patients exhibit altered BDNF levels in the brain and blood, and conversely, several animal studies demonstrate a potential protective effect of BDNF against Aβ-induced neurotoxicity.

In serum, many studies have reported a reduction of BDNF levels in AD patients as compared to healthy subjects. In addition, patients with mild cognitive impairment (MCI) may also be characterized by decreased BDNF levels as compared to controls. Furthermore, decreased levels of BDNF in MCI and AD patients seem to be associated with hippocampal structural changes and
decrease in cognitive performance. Despite these evidences, there is still a lack of consensus about BDNF profile in AD patients. Other studies have in fact reported either increased BDNF levels in both MCI and AD patients or no difference between AD and controls.

Likewise, studies on cerebrospinal fluid (CSF) BDNF levels in AD and other dementias report similar results. Forlenza et al found decreased BDNF concentration in CSF, associated with faster progression from amnestic MCI to AD. Blasko et al did not find a significant difference in BDNF between AD and controls, while Laske et al showed lower CSF BDNF levels among AD patients in comparison with healthy controls and non-AD dementia patients. Furthermore, a study in healthy older adults showed an association of lower CSF BDNF levels with poorer memory performance and faster cognitive decline.

In the brain of AD patients, it was found that both BDNF mRNA and protein levels are reduced in hippocampus and temporal cortex while protein levels are reduced in the hippocampus and the parietal cortex. Other studies have shown that the pro-BDNF is also reduced in parietal cortex and in nucleus basalis of Meynert (nbM) of AD patients and this decrease precedes the decline in choline acetyltransferase activity. To the best of our knowledge, there are no data on pro-BDNF measurement in the serum or CSF of AD patients. There are also data indicating changes in BDNF receptor in the brain of AD patients. One study showed a consistent reduction of TrkB immunoreactive neurons in the nbM of AD patients while other studies reported no changes in TrkB receptor.

These data have generated the consensus that in the brain of AD patients, there is a lack of BDNF support to neurons, which can contribute to synaptic dysfunction, cognitive decline, and lately to neuronal death. Nonetheless, the mechanism by which aggregated or soluble Ap forms interfere with BDNF activity in neurons is not yet clear. In the following paragraph, we will describe a possible relationship between plasminogen activation system and BDNF at the synaptic level.

**FIGURE 1** Relationship between plasminogen activation system and BDNF at the synaptic level. tPA and PAI-1 may be released into the extracellular space where plasminogen is also present. tPA can influence synaptic activity by two ways: (1) by binding directly to specific subunits of NMDA receptors and (2) by increasing the levels of plasmin, which in turn leads to increased BDNF maturation and increased synaptic activity (LTP) after binding with the TrkB receptor. PAI-1 inhibits tPA activity, thus reducing the synthesis of plasmin and the maturation of BDNF. In the context of Alzheimer's disease, elevated PAI-1 levels may account for increased Ap accumulation and increased pro-BDNF, which reduces synaptic function (LTD) after binding with the p75 receptor. Long-term consequences may include cognitive deficits and fostering of neurodegenerative processes.
pathogenic mechanism caused by soluble Aβ forms based on the effects on tPA/PAI-1 system and, as illustrated previously, the consequence of an altered conversion from pro-BDNF to the mature BDNF.

8 | PATHOGENIC MECHANISM OF Aβ SOLUBLE FORMS IN AD THROUGH CHANGES IN TPA, PAI-1, AND BDNF

Synaptic dysfunction plays an important role in AD pathophysiology. As said before, the most recent hypotheses in AD involve soluble forms of Aβ, which play an important role in causing cognitive deficits by specifically targeting synaptic sites and disrupting signaling pathways. Nonetheless, the molecular details of this process have not been fully elucidated.

The data exposed above suggest that one of the possible mechanisms by which soluble Aβ forms affect synaptic function is linked to the changes observed in the tPA/PAI-1 system and, consequently, to the effects on pro-BDNF/BDNF ratio (Figure 1). Supporting this hypothesis, a recent study with a mouse genetic model of familial AD (Tg2576) and post-mortem brain tissues has shown that Aβ soluble forms might impair BDNF proteolytic processing through modulation of neuronal PAI-1.

Thus, one plausible hypothesis is that elevated levels of PAI-1 in AD inhibit the synthesis of plasmin by tPA. The consequences of this inhibition in the brain may be multiple. First, a reduced synthesis of plasmin may contribute to Aβ accumulation in the brain and thus accelerate the disease process. Second, a reduced plasmin synthesis may lead to reduced extracellular conversion of pro-BDNF to BDNF. An altered ratio of pro-BDNF/BDNF in favor of the pro-form may lead to an enhancement of LTD and to a reduction of LTP in hippocampal neurons, with consequent synaptic dysfunction and memory deficits. Lastly, a long-lasting reduction of mature BDNF, which is the most important neurotrophic factor in the CNS, may contribute to neuronal atrophy and ultimately to neuronal death. A scheme summarizing this mechanism is represented in Figure 2.

9 | DIAGNOSTIC AND THERAPEUTIC IMPLICATIONS IN AD

Based on the data presented, there are some important considerations from both diagnostic and therapeutic points of view.

The therapies available for AD treatment are only able to slow down but not to stop the disease progression. In this scenario, the prevention and an early diagnosis are important tools to increase the quality of life of these patients and to reduce the costs to the families and to the public healthcare system. Additional use of biomarkers could make the AD diagnosis easier and faster, as already demonstrated for Aβ 1-42 and tau in CSF.110

**FIGURE 2** Putative scheme of pathogenic mechanism of amyloid beta soluble forms in AD through tPA/PAI-1 and BDNF. By upregulating PAI-1, Aβ soluble forms inhibit tPA and plasmin synthesis. This mechanism impairs the extracellular conversion from pro-BDNF to the mature BDNF. An altered ratio of pro-BDNF/BDNF in favor of the pro-form may lead to an enhancement of LTD and reduction of LTP in hippocampal neurons, with consequent synaptic dysfunction and memory deficits. In addition, a long-lasting reduction of mature BDNF may contribute to neuronal atrophy and death. Aβ: amyloid beta; BDNF: brain-derived neurotrophic factor; PAI-1: plasminogen-activator inhibitor-1; tPA: tissue plasminogen-activator
The data presented here suggest that measurement of BDNF/pro-BDNF ratio and tPA/PAI-1 ratio in biological fluids (serum, plasma, CSF), in association with neuroimaging data and neuropsychological characterization, may serve as indirect indicators of the "synaptic state" in the brain of AD subjects. If a direct connection between these biomarkers and cognitive decline could be established, there will be the possibility to treat the patients according to their risk of developing severe or moderate forms of dementia. Testing these protein levels in blood is a quite simple procedure, without risk for the patient, conventionally used in most of laboratory analysis. Notably, the strategy of combined measures of tPA-BDNF pathway proteins in serum (including pro-BDNF) has been recently adopted in subjects affected by different mental disorders. The results have shown that the combined measures of protein levels of the tPA-BDNF pathway were better than single protein measurement, in terms of accuracy of diagnosis and differentiation of these disorders.66,111

In addition, investigation of proteins involved in synaptic regulation and neuronal survival, such as BDNF and the related proteins described here, will give a significant contribution to the understanding of pathophysiology of AD and an incentive to develop therapeutic strategies based on the targeting of elements of the pathway involved. The modulation of brain BDNF (and other related trophic factors) has already been investigated as potential treatment strategy in a large group of CNS disorders including AD.54,112,113 AD and Parkinson's diseases, amyotrophic lateral sclerosis, Huntington's disease, and peripheral neuropathy. Most of the trials, however, have failed because of the difficulty of these proteins to cross the blood–brain barrier and to deliver the right amount of trophic factor in the target region. Instead, the tPA/PAI-1 pathway can be targeted by pharmacological agents,54 a strategy that has been already adopted in other types of diseases such as diabetic nephropathy and fibrosis.115 However, there is a need to explore the effects of these agents on BDNF expression in healthy and AD subjects.

Interestingly, a recent study has shown that administration of a PAI-1 inhibitor for a period of 6 weeks reduces Aβ load in the hippocampus and cortex and improve learning and memory function in an AD mouse model.116 Notably, these effects were associated with increased tPA and plasmin activities. Furthermore, in a multiple sclerosis mouse model, it was shown that oral administration of another PAI-1 inhibitor (TM54B84) with high capacity to penetrate the blood–brain barrier was able to up-regulate gene expression of BDNF and choline acetyltransferase, a marker of cholinergic neuronal density.117 These effects were associated to reduced demyelination and axonal degeneration. In another in vitro study, it was shown that PAI-1 inhibitors are able to reduce pro-BDNF levels in hippocampal slices from epileptic mice.118 These data suggest that the compounds targeting tPA/PAI-1 pathway, such as PAI-1 inhibitors, may represent a new strategy to modulate brain BDNF expression in pathological conditions, including AD.

**ADDITIONAL CONSIDERATIONS AND LIMITATIONS**

In this review, we have hypothesized that Aβ soluble forms may impair PAI-1/tPA pathway in the CNS and consequently cause effects on the conversion of pro-BDNF to the mature BDNF. Despite the evidences provided, we should be aware that there is at present no conclusive evidence that this is the sole mechanism occurring in the brain of AD patients. Thus, we cannot exclude the possibility that PAI-1 may increase independently from the effect of Aβ and that Aβ itself accumulates because of high PAI-1 expression/activity. It is likely that the two effects are interconnected and sustain each other with a vicious circle. In addition, there is a body of evidence indicating that Aβ might be involved in the decrease of BDNF in AD. In rat models, injection of Aβ reduces BDNF content in brain regions such as frontal cortex and amygdala.119 Moreover, neuroblastoma cells and dendritic cells derived from AD patients cultured in the presence of Aβ display down-regulation of BDNF protein and mRNA.120,121 It has been suggested that Aβ may interfere with BDNF synthesis by acting on the transcription factor- cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB) binding to the promoter region of BDNF, leading to decreased BDNF transcription.120,122 Alternatively, the structural changes induced by Aβ at the levels of microtubules interfere with BDNF axonal transport.123,124 On the other hand, there are also consisting evidences for the neuroprotective effect of BDNF against Aβ-induced neurotoxicity. Exogenous application of BDNF reduced Aβ production in primary neurons and in the brain of wild-type mice in vivo.125 In addition, BDNF is able to provide neuroprotection and improve learning and memory deficits induced by previous Aβ administration.126

In any case, the interconnection among the effects of Aβ, BDNF and the plasminogen activation system suggests that, independently from its origin, this mechanism might be responsible for many clinical features of AD and that a pharmacological treatment targeting elements of this circuit, such as for example PAI-1, is likely to produce a cascade effect.

**CONCLUSIONS**

Aβ soluble forms have been claimed to be responsible for AD pathological symptoms by specifically targeting synapses and disrupting synaptic signaling pathways. Recent data have suggested that one of the targets of Aβ soluble forms may be the enzymatic elements of the plasminogen activation system. The direction of changes of these enzymes points to a down-regulation of tPA and to an up-regulation of its inhibitor PAI-1.

In this review, we have explored the data supporting the hypothesis that the process of conversion of BDNF, a strong regulator of synaptic activity in brain neurons, from the immature form pro-BDNF to the mature form may be altered by tPA/PAI-1 changes in AD. By up-regulating PAI-1, Aβ soluble forms may impair this conversion and cause an altered extracellular BDNF/pro-BDNF ratio. The
combined effects of Aβ soluble forms on BDNF and tPA/PAI-1 may account for many AD symptoms, including synaptic dysfunctions, memory deficits, and neuronal death. Therefore, a pharmacological approach based on the targeting of tPA/PAI-1 system could produce beneficial effects on AD symptoms, possibly by modulation of BDNF gene expression.

ACKNOWLEDGMENTS

All authors contributed to the work and approved the final version. The work has not been published before nor is it being considered for publication in another journal.

CONFLICT OF INTEREST

All authors declare no conflict of interest.

ORCID

Francesco Angelucci https://orcid.org/0000-0002-5956-5925
Richard Průša https://orcid.org/0000-0001-6408-7086

REFERENCES

1. Holtzman DM, Morris JC, Goate AM. Alzheimer’s disease: the challenge of the second century. Sci Transl Med. 2011;3:77sr1.
2. Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010;362:329-344.
3. Cavallucci V, D’Amelio M, Cecconi F. Aβ toxicity in Alzheimer’s disease. Mol. Neurobiol. 2012;45:366-378.
4. Price JL, Morris JC. Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol. 1999;45:358-368.
5. Aizenstein HJ, Nebes D, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509-1517.
6. Lesné S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440:352-357.
7. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med. 2008;14:837-842.
8. Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritotoxic degeneration. Proc Natl Acad Sci USA. 2011;108:5819-5824.
9. Koffie RM, Meyer-Luehmann M, Hashimoto T, et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA. 2009;106:4012-4017.
10. Tu S, Okamoto S, Lipton SA, Xu H. Oligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease. Mol Neurodegener. 2014;9:48.
11. Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ. Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci. 2011;31:6627-6638.
12. Brody DL, Jiang H, Wildburger N, Esparza TJ. Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer’s disease. Alzheimers Res Ther. 2017;9:62.
13. Smith LM, Strittmatter SM. Binding sites for amyloid-β oligomers and synaptic toxicity. Cold Spring Harb Perspect Med. 2017;7:a024075.
14. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016;8:595-608.
15. Yang T, Li S, Xu H, Walsh DM, Selkoe DJ. Large soluble oligomers of amyloid β-protein from Alzheimer brain are far less neuroactive than the smaller oligomers to which they dissociate. J Neurosci. 2017:37:152-163.
16. Dietrich K, Bouter Y, Müller M, Bayer TA. Synaptic alterations in mouse models for Alzheimer disease—a special focus on N-truncated Abeta 4–42. Molecules. 2018;23:E718.
17. Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148:1204-1222.
18. Castellino FJ, Plopalis VA. Structure and function of the plasminogen/plasmin system. Thromb Haemost. 2005;93:647-654.
19. Bugge TH, Flick MJ, Danton MJ, et al. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA. 1996;93:5899-5904.
20. Samson AL, Medcalf RL. Tissue-type plasminogen activator: a multifaceted modulator of neurotransmission and synaptic plasticity. Neuron. 2006;50:673-678.
21. Yepes M, Roussel BD, Ali C, Vivien D. Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. Trends Neurosci. 2009;32:48-55.
22. Huang YY, Bach ME, Lipp HP, et al. Mice lacking the gene encoding tissue-type plasminogen activator show a selective interference with late-phase long-term potentiation in both Schaffer collateral and mossy fiber pathways. Proc Natl Acad Sci USA. 1996;93:8699-8704.
23. Madani R, Hulo S, Toni N, et al. Enhanced hippocampal long-term potentiation and learning by increased neuronal expression of tissue-type plasminogen activator in transgenic mice. EMBO J. 1999;18:3007-3012.
24. Zhuo M, Holtzman DM, Li Y, et al. Role of tissue plasminogen activator receptor LRP in hippocampal long-term potentiation. J Neurosci. 2000;20:542-549.
25. Gualandris A, Jones TE, Strickland S, Tsirka SE. Membrane depolarization induces calcium-dependent secretion of tissue plasminogen activator. J Neurosci. 1996;16:2220-2225.
26. Parmer RJ, Mahata M, Mahata S, et al. Tissue plasminogen activator (t-PA) is targeted to the regulated secretory pathway. J Biol Chem. 1997;272:1976-1982.
27. Qian Z, Gilbert ME, Colicos MA, Kandel ER, Kuhl D. Tissue plasminogen activator is induced as an immediate-early gene during seizure, kindling, and long-term potentiation. Nature. 1993;361:453-457.
28. Carroll PM, Tsirka SE, Richards WG, Frohman MA, Strickland S. The mouse tissue plasminogen activator gene 5’ flanking region confers tissue specificity of plasminogen cleavage in the ischemic brain: more than a thrombolytic. Trends Pharmacol Sci. 2004;25:337-341.
29. Calabresi P, Napolitano M, Centonze D, et al. Tissue plasminogen activator controls multiple forms of synaptic plasticity and memory. Front Cell Neurosci. 2017;11:427.
33. Tucker HM, Kihiko M, Caldwell JN, et al. The plasmin system is induced by and degrades amyloid-beta aggregates. J Neurosci. 2000;20:3937-3946.
34. Tucker HM, Kihiko-Ehmann M, Wright S, et al. Tissue plasminogen activator requires plasminogen to modulate amyloid-beta neurotoxicity and deposition. J Neurochem. 2000;75:2172-2177.
35. Barker R, Love S, Kehoe PG. Plasminogen and plasmin in Alzheimer’s disease. Brain Res. 2010;1355:7-15.
36. Jacobsen JS, Comery TA, Martone RL, et al. Enhanced clearance of A beta in brain by sustaining the plasminogen proteolysis cascade. Proc Natl Acad Sci USA. 2008;105:8754-8759.
37. Ledesma MD, Abad-Rodriguez J, Galvan C, et al. Raft disorganization leads to reduced plasmin activity in Alzheimer’s disease brains. EMBO Rep. 2003;4:1190-1196.
38. Ledesma MD, da Silva JS, Cressaerts K, Delacourte A, de Strooper B, Dotti CG. Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer’s disease brains. EMBO Rep. 2000;1:530-535.
39. Oh SB, Byun CJ, Yun JH. Tissue plasminogen activator arrests Alzheimer’s disease pathogenesis. Neurobiol Aging. 2014;35:511-519.
40. Bi Oh S, Suh N, Kim I, Lee J-Y. Impacts of aging and amyloid-beta deposition on plasminogen activators and plasminogen activator inhibitor-1 in the Tg2576 mouse model of Alzheimer’s disease. Brain Res. 2015;1597:159-167.
41. Fabbro S, Seeds NW. Plasminogen activator activity is inhibited while neuroserpin is up-regulated in the Alzheimer disease brain. J Neurochem. 2009;109:303-315.
42. Cacquevel M, Launay S, Castel H, et al. Ageing and amyloid-beta peptide deposition contribute to an impaired brain tissue plasminogen activator activity by different mechanisms. Neurobiol Dis. 2007;27:164-173.
43. Medina MG, Ledesma MD, Dominguez JE, et al. Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation. EMBO J. 2005;24:1706-1716.
44. Barker R, Kehoe PG, Love S. Activators and inhibitors of the plasminogen system in Alzheimer’s disease. J Cell Mol Med. 2012;16:865-876.
45. Wang J, Yuan Y, Cai R, et al. Association between plasma levels of PAI-1, tPA/PAI-1 molar ratio, and mild cognitive impairment in Chinese patients with Type 2 diabetes mellitus. J Alzheimer Dis. 2018;63:835-845.
46. Liu RM, van Groen T, Katre A. Knockout of plasminogen activator inhibitor-1 in the mouse model of Alzheimer’s disease. Neurobiol Aging. 2011;32:1079-1089.
47. Oh J, Lee HJ, Song JH, Park SI, Kim H. Plasminogen activator inhibitor-1 as an early potential diagnostic marker for Alzheimer’s disease. Exp Gerontol. 2014;60:87-91.
48. Melchor JP, Pawlak R, Strickland S. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. J Neurosci. 2003;23:8867-8871.
49. Buisson A, Nicole O, Docagne F, Sartelet H, Mackenzie ET, Vivien D. Up-regulation of a serine protease inhibitor in astrocytes mediates the neuroprotective activity of transforming growth factor beta1. FASEB J. 1998;12:1683-1691.
50. Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest. 1991;88:1346-1353.
51. Hino H, Akiyama H, Iseki E, et al. Immunohistochemical localization of plasminogen activator inhibitor-1 in rat and human brain tissues. Neurosci Lett. 2001;297:105-108.
52. Podor TJ, Joshua P, Butcher M, Seiffert D, Loskutoff D, Gauldie J. Accumulation of type 1 plasminogen activator inhibitor and vitronectin at sites of cellular necrosis and inflammation. Ann N Y Acad Sci. 1992;667:173-177.
53. Holmes C. Review: systemic inflammation and Alzheimer’s disease. Neuropathol Appl Neurobiol. 2013;39:51-68.
54. Gerenu G, Martinova E, Ferrero H, et al. Modulation of BDNF cleavage by plasminogen-activator inhibitor-1 contributes to Alzheimer’s neuropathology and cognitive deficits. Biochim Biophys Acta. 2017;1863:991-1001.
55. Morishima Y, Gotoh Y, Zieg J, et al. Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J Neurosci. 2001;21:7551-7560.
56. Descheemaeker KA, Wyns S, Nelles L, Uawerx J, Ny T, Collen D. Interaction of AP-1, AP-2, and Sp1-like proteins with two distinct sites in the upstream regulatory region of the plasminogen activator inhibitor-1 gene mediates the phorbol 12-myristate 13-acetate response. J Biol Chem. 1992;267:15086-15091.
57. Gray K, Ellis V. Activation of pro-BDNF by the pericellular proteolysis of plasmin. FEBS Lett. 2008;582:907-910.
58. Mou X, Peterson CB, Prosser RA. Tissue-type plasminogen activator-plasmin-·BDNF modulate glutamate-induced phase-shifts of the mouse suprasylvian circadian clock in vitro. Eur J Neurosci. 2009;30:1451-1460.
59. Melchor JP, Strickland S. Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost. 2005;93:655-660.
60. Sakuragi S, Tominaga-Yoshino K, Ogura A. Involvement of TrkB- and p75(NTR)-signaling pathways in two contrasting forms of long-lasting synaptic plasticity. Sci Rep. 2013;3:3185.
61. Rodier M, Prigent-Tessier A, Béjot Y, et al. Exogenous tPA administration increases hippocampal mature BDNF levels. plasmin- or NMDA-dependent mechanism? PLoS One 2014;9:e92416.
62. Pang PT, Lu B. Regulation of late-phase LTP and long-term memory in normal and aging hippocampus: role of secreted proteins tPA and BDNF. Ageing Res Rev. 2004;3:407-430.
63. Pang PT, Teng HK, Zaitsev E, et al. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science. 2004;306:487-491.
64. Hsu CD, Tsai SJ. The tissue plasminogen activator/plasmin system may act through cleavage of pro-BDNF to increase risk of substance abuse. CNS Spects. 2010;15:350.
65. Bachis A, Campbell LA, Jenkins K, Wenzel E, Mocchetti I. Morphine withdrawal increases brain-derived neurotrophic factor precursor. Neurotox Res. 2017;32:509-517.
66. Jiang H, Chen S, Li C, et al. The serum protein levels of the tPA/BDNF pathway are implicated in depression and antidepressant treatment. Transl Psychiatry. 2017;7:e1079.
67. Tsai SJ. Role of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in psychological stress and depression. Oncotarget. 2017;8:113258-113268.
68. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci. 2001;24:677-736.
69. Hong EJ, McCord AE, Greenberg ME. A biological function for the neuronal activity-dependent component of Bdnf transcription in the development of cortical inhibition. Neuron. 2008;60:610-624.
70. Mowla SJ, Pareek S, Farhadi HF, et al. Differential sorting of nerve growth factor and brain-derived neurotrophic factor in hippocampal neurons. J Neurosci. 1999;19:2069-2080.
71. Wetsel WC, Rodriguez RM, Guillenot J, et al. Disruption of the expression of the proproteinconvertasePC7reducesBDNFproduction and affects learning and memory in mice. Proc Natl Acad Sci USA. 2013;110:17362-17367.
72. Nagahara AH, Merrill DA, Coppola G, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer’s disease. Nat Med. 2009;15:331-337.

73. Teng HK, Teng KK, Lee R, et al. ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. J Neurosci. 2005;25:5455-5463.

74. Lee R, Kermari P, Teng KK, et al. Regulation of cell survival by secreted proneurotrophins. Science. 2001;294:1945-1948.

75. Anastasia A, Deinhardt K, Chao MV, et al. Val66Met polymorphism of BDNF alters prdomain structure to induce neuronal growth cone retraction. Nat Commun. 2013;4:2490.

76. Lehof AM, Ip NY, Poo MM. Potentiation of developing neuromuscular synapses by the neurotrophins NT-3 and BDNF. Nature. 1993;363:350-353.

77. Leal G, Bramham CR, Duarte CB. BDNF and Hippocampal Synaptic Plasticity. Vitam Horm. 2017;104:153-195.

78. Yang J, Harte-Hargrove LC, Siao CJ, et al. proBDNF negatively regulates neuronal remodeling, synaptic transmission, and synaptic plasticity in hippocampus. Cell Rep. 2014;7:796-806.

79. Sun Y, Lim Y, Li F, et al. ProBDNF collapses neurite outgrowth of primary neurons by activating RhoA. PLoS One. 2012;7:e35883.

80. Woo NH, Teng HK, Siao CJ, et al. Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. Nat Neurosci. 2005;8:1069-1077.

81. Lu Y, Christian K, Lu B. BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory? Neurobiol Learn Mem. 2008;90:312-323.

82. Je HS, Yang F, Ji Y, et al. Role of pro-brain-derived neurotrophic factor (proBDNF) to mature BDNF conversion in activity-dependent competition at developing neuromuscular synapses. Proc Natl Acad Sci USA. 2012;109:15924-15929.

83. Lu B, Pang PT, Woo NH. The yin and yang of neurotrophin action. Nat Rev. Neurosci. 2005;6:603-614.

84. Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. J Alzheimers Dis. 2009;5:311-322.

85. Turana Y, Ranakusuma T, Purba JS, et al. Enhancing diagnostic accuracy of amCMI in the elderly: combination of olfactory test, pupillary response test, BDNF plasma level, and APOE genotype. Int J Alzheimers Dis. 2014;2014:912586.

86. Chen J, Zhang T, Jiao S, et al. Precursor form of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment. World J Biol Psychiatry. 2010;11:774-780.

87. Shima H, Makizako H, Doi T, et al. A large, cross-sectional observational study of serum BDNF, cognitive function, and mild cognitive impairment in the elderly. Front Aging Neurosci. 2014;6:69.

88. O’Bryant SE, Hobson V, Hall JR, et al. Brain-derived neurotrophic factor levels in Alzheimer’s disease. J Alzheimers Dis. 2009;17:337-341.

89. Forlenza OV, Diniz BS, Teixeira AL, et al. Lower cerebrospinal fluid concentration of brain-derived neurotrophic factor predicts progression from mild cognitive impairment to Alzheimer’s disease. Neuromolecular Med. 2015;17:326-332.

90. Blasko I, Lederer W, Oberbauer H, et al. Measurement of thirteen biological markers in CSF of patients with Alzheimer’s disease and other dementias. Dement Geriatr Cogn Disord. 2006;21:9-15.

91. Li G, Peskind ER, Millard SP, et al. Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects. PLoS One. 2009;4:e5424.

92. Connor B, Young D, Yan Q, Faull RL, SynckB DM. Brain-derived neurotrophic factor is reduced in Alzheimer’s disease. Brain Res. Mol Brain Res. 1997;9:71-81.

93. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s disease. Neuron. 1991;7:695-702.

94. Hock C, Heese K, Hulette C, Rosenberg C, Otten U. Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol. 2000;57:846-851.

95. Michalski B, Fahnstock M. Pro-brain-derived neurotrophic factor is decreased in parietal cortex in Alzheimer’s disease. Brain Res Mol Brain Res. 2003;111:148-154.

96. Fahnstock M, Garzon D, Holsinger RM, Michalski B. Neurotrophic factors and Alzheimer’s disease: are we focusing on the wrong molecule? J Neural Transm Suppl. 2002;62:241-252.

97. Peng S, Wuu J, Mufson EJ, Fahnstock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer’s disease. J Neurochem. 2005;93:1412-1421.

98. Salehi A, Verhaagen J, Dijkhuizen PA, Swaab DF. Co-localization of high-affinity neurotrophin receptors in nucleus basalis of Meynert neurons and their differential reduction in Alzheimer’s disease. Neuroscience. 1996;75:373-387.

99. Michalski B, Fahnstock M. Pro-brain-derived neurotrophic factor is decreased in parietal cortex in Alzheimer’s disease. Brain Res Mol Brain Res. 2003;111:148-154.

100. Borba EM, Duarte JA, Bristot G, Scotton E, Camozzato AL, Chaves ML. Brain-derived neurotrophic factor serum levels and hippocampal volume in mild cognitive impairment and dementia due to Alzheimer disease. Dement Geriatr Cogn Dis Extra. 2016;6:559-567.

101. Geesen-Ak D, Dursun E, Hanajias H, et al. BDNF, TNFα, HSP90, CFH, and IL-10 serum levels in patients with early or late onset Alzheimer’s disease or mild cognitive impairment. J Alzheimers Dis. 2013;37:185-195.

102. Blasko I, Lederer W, Oberbauer H, et al. Measurement of thirteen biological markers in CSF of patients with Alzheimer’s disease and other dementias. Dement Geriatr Cogn Disord. 2006;21:9-15.

103. Hock C, Heese K, Muller-Spahn F, Hulette C, Rosenberg C, Otten U. Decreased trkA neurotrophin receptor expression in the parietal cortex of patients with Alzheimer’s disease. Neurosci Lett. 1998;241:151-154.

104. Savaskan E, Muller-Spahn F, Olivier G, et al. Alterations in trk A, trk B and trk C receptor immunoreactivities in parietal cortex and cerebellum in Alzheimer’s disease. Eur Neurol. 2000;44:172-180.

105. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. J Cereb Blood Flow Metab. 2015;35:1997-2016.

106. Passaro A, Dalla Nora E, Morieri ML, et al. Brain-derived neurotrophic factor plasma levels: relationship with dementia and diabetes in the elderly population. J Gerontol A Biol Sci Med Sci. 2006;113:1217-1224.

107. Psotta L, Rockahr C, Gruss M, et al. Impact of an additional chronic BDNF reduction on learning performance in an Alzheimer mouse model. Front Behav Neurosci. 2015;9:58.

108. Borba EM, Duarte JA, Bristot G, Scotton E, Camozzato AL, Chaves ML. Brain-derived neurotrophic factor serum levels and hippocampal volume in mild cognitive impairment and dementia due to Alzheimer disease. Dement Geriatr Cogn Dis Extra. 2016;6:559-567.

109. Allen SJ, Dawbarn D. Clinical relevance of the neurotrophins and their receptors. Clin Sci (Lond). 2006;110:175-191.
113. Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov. 2011;10:209-219.

114. Jeong BY, Uddin MJ, Park JH, et al. Novel plasminogen activator inhibitor-1 inhibitors prevent diabetic kidney injury in a mouse model. PLoS One. 2016;11:e0157012.

115. Huang WT, Vayalil PK, Miyata T, Hagood J, Liu RM. Therapeutic value of small molecule inhibitor to plasminogen activator inhibitor-1 for lung fibrosis. Am J Respir Cell Mol Biol. 2012;46:87-95.

116. Akhter H, Huang WT, van Groen T, Kuo HC, Miyata T, Liu RM. A small molecule inhibitor of plasminogen activator inhibitor-1 reduces brain amyloid-β load and improves memory in an animal model of Alzheimer's disease. J Alzheimers Dis. 2018;64:447-457.

117. Pelisch N, Dan T, Ichimura A, et al. Plasminogen activator inhibitor-1 antagonist TM5484 attenuates demyelination and axonal degeneration in a mice model of multiple sclerosis. PLoS One. 2015;10:e0124510.

118. Thomas AX, Cruz Del Angel Y, Gonzalez MI, et al. Rapid increases in proBDNF after pilocarpine-induced status epilepticus in mice are associated with reduced proBDNF cleavage machinery. eNeuro 2016;3:ENEURO.0020-15.2016.

119. Zussy C, Brureau A, Keller E, et al. Alzheimer's disease related markers, cellular toxicity and behavioral deficits induced six weeks after oligomeric amyloid-beta peptide injection in rats. PLoS One. 2013;8:e53117.

120. Garzon DJ, Fahnestock M. Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. J Neurosci Off J Soc Neurosci. 2007;27:2628-2635.

121. Ciaramella A, Salani F, Bizzoni F, et al. The stimulation of dendritic cells by amyloid beta 1-42 reduces BDNF production in Alzheimer's disease patients. Brain Behav Immun. 2013;32:29-32.

122. Liu R, Zhang TT, Zhou D, et al. Quercetin protects against the Abeta(25–35)-induced amnesic injury: involvement of inactivation of rage-mediated pathway and conservation of the NVU. Neuropharmacology. 2013;67:419-431.

123. Poon WW, Blurton-Jones M, Tu CH, et al. beta-Amyloid impairs axonal BDNF retrograde trafficking. Neurobiol Aging. 2011;32:821-833.

124. Ye X, Tai W, Zhang D. The early events of Alzheimer's disease pathology: from mitochondrial dysfunction to BDNF axonal transport deficits. Neurobiol Aging. 2012;33(1122):pp. e11121-1122.

125. Rohe M, Synowitz M, Glass R, Paul SM, Nykjaer A, Willnow TE. Brain-derived neurotrophic factor reduces amyloidogenic processing through control of SORLA gene expression. J Neurosci Off J Soc Neurosci. 2009;29:15472-15478.

126. Zhou JP, Feng ZG, Yuan BL, et al. Transduced PTD-BDNF fusion protein protects against beta amyloid peptide-induced learning and memory deficits in mice. Brain Res. 2008;1191:12-19.

How to cite this article: Angelucci F, Čechová K, Průša R, Hort J. Amyloid beta soluble forms and plasminogen activation system in Alzheimer's disease: Consequences on extracellular maturation of brain-derived neurotrophic factor and therapeutic implications. CNS Neurosci Ther. 2019;25:303–313. https://doi.org/10.1111/cns.13082